We demonstrate the usefulness of the developed workflow on the basis of two different use cases: a rare disease (here: Glucose Transporter Type 1 (GLUT-1) deficiency), and a new disease (here: COVID 19). This evidence concerns the gene SLC2A1 and hyperinsulinemic hypoglycemia, familial, 4.